c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms c-TRAK-TN
- 26 Jan 2018 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 26 Jan 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.
- 11 May 2017 New trial record